Citadel Advisors
TAK icon

Citadel Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Citadel Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607K Buy
+32,800
New +$576K ﹤0.01% 8818
2025
Q4 		– Sell
-10,200
Closed -$149K – 14042
2025
Q3 		$149K Buy
+10,200
New +$151K ﹤0.01% 11534
2025
Q2 		– Sell
-1,300
Closed -$19.3K – 15020
2025
Q1 		$19.3K Sell
1,300
-12,800
-91% -$179K ﹤0.01% 13168
2024
Q4 		$187K Buy
14,100
+7,600
+117% +$104K ﹤0.01% 10566
2024
Q3 		$92.4K Buy
6,500
+700
+12% +$9.93K ﹤0.01% 11228
2024
Q2 		$75.1K Buy
5,800
+3,600
+164% +$47.7K ﹤0.01% 11285
2024
Q1 		$30.6K Sell
2,200
-30,800
-93% -$448K ﹤0.01% 12684
2023
Q4 		$471K Sell
33,000
-42,000
-56% -$596K ﹤0.01% 8243
2023
Q3 		$1.16M Sell
75,000
-2,200
-3% -$34.1K ﹤0.01% 6263
2023
Q2 		$1.21M Sell
77,200
-23,500
-23% -$385K ﹤0.01% 6066
2023
Q1 		$1.66M Sell
100,700
-26,400
-21% -$421K ﹤0.01% 5726
2022
Q4 		$1.98M Buy
127,100
+18,000
+16% +$251K ﹤0.01% 5506
2022
Q3 		$1.42M Buy
109,100
+8,000
+8% +$111K ﹤0.01% 6268
2022
Q2 		$1.42M Sell
101,100
-35,400
-26% -$505K ﹤0.01% 6238
2022
Q1 		$1.96M Sell
136,500
-140,700
-51% -$2.07M ﹤0.01% 6131
2021
Q4 		$3.78M Buy
277,200
+95,900
+53% +$1.35M ﹤0.01% 4867
2021
Q3 		$2.97M Sell
181,300
-2,900
-2% -$48.7K ﹤0.01% 5390
2021
Q2 		$3.1M Sell
184,200
-81,000
-31% -$1.38M ﹤0.01% 5520
2021
Q1 		$4.84M Sell
265,200
-288,197
-52% -$5.19M ﹤0.01% 4320
2020
Q4 		$10.1M Buy
553,397
+40,497
+8% +$711K ﹤0.01% 2634
2020
Q3 		$9.15M Sell
512,900
-6,300
-1% -$115K ﹤0.01% 2389
2020
Q2 		$9.31M Buy
519,200
+10,400
+2% +$187K ﹤0.01% 2310
2020
Q1 		$7.72M Sell
508,800
-142,200
-22% -$2.58M ﹤0.01% 2165
2019
Q4 		$12.8M Buy
651,000
+1,400
+0.2% +$26.8K 0.01% 1942
2019
Q3 		$11.2M Buy
649,600
+700
+0.1% +$12.1K 0.01% 2086
2019
Q2 		$11.5M Buy
648,900
+404,600
+166% +$7.36M 0.01% 2016
2019
Q1 		$4.98M Buy
+244,300
New +$4.92M ﹤0.01% 3004

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's TAK Position: Q1 2026 in Review

Citadel Advisors increased its Takeda Pharmaceutical (TAK) stake by 60% in Q1 2026, buying an estimated $4.11M and bringing the position to 624,160 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

Citadel Advisors first reported a position in TAK in Q4 2018 and has held it in 28 quarters since. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Citadel Advisors held 624,160 shares of Takeda Pharmaceutical worth $11.6M as of Q1 2026.
  • Citadel Advisors bought 234,426 Takeda Pharmaceutical shares in Q1 2026, an estimated $4.11M.
  • Takeda Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3052 holding.
  • Citadel Advisors first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 28 quarters since.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.